Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04300244
Title Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma (NIPU)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Aslaug Helland

malignant pleural mesothelioma


Ipilimumab + Nivolumab + UV1 Telomerase peptide vaccine

Ipilimumab + Nivolumab

Age Groups: adult | senior
Covered Countries ESP

No variant requirements are available.